Key facts
- Pathos AI’s last known valuation is $1.6B (May 2025).
- It has raised $467.0M across 3 recorded rounds; the latest was Later Stage VC ($283.0M) in Apr 2025.
- Notable investors include New Enterprise Associates, Builders VC, Lightbank (Venture Capital), Eric Lefkofsky, Revolution (Washington DC).
- Pathos AI has filed 3 Form Ds with the SEC since 2023, most recently May 2025 ($283.0M sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pathos AI
Funding rounds
3 roundsAbout Pathos AI
Developer of a drug discovery platform designed to reduce the duration of the medication development process. The company's self-learning platform uses big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy, enabling drug developers to explore novel concepts and advance breakthrough therapies for cancer and other diseases.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2020
- Employees
- 85
- Website
- pathos.com/
- Ownership
- Privately Held (backing)
Pathos AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pathos AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pathos AI in its N-PORT filings yet. We sweep new filings monthly.